Development of a Bispecific Antibody Targeting CD30 and CD137 on Hodgkin and Reed-Sternberg Cells.
CD137
CD30
Hodgkin lymphoma
bispecific antibodies
immunotherapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2019
2019
Historique:
received:
07
01
2019
accepted:
09
09
2019
entrez:
17
10
2019
pubmed:
17
10
2019
medline:
17
10
2019
Statut:
epublish
Résumé
Hodgkin Lymphoma (HL) is a malignancy that frequently affects young adults. Although, there are effective treatments not every patient responds, necessitating the development of novel therapeutic approaches, especially for relapsed and refractory cases. The two TNF receptor family members CD30 and CD137 are expressed on Hodgkin and Reed Sternberg (HRS) cells, the malignant cells in HL. We found that this co-expression is specific for HRS cells. Based on this discovery we developed a bispecific antibody that binds preferentially to the CD30, CD137-double positive HRS cells. The CD30, CD137 bispecific antibody gets internalized into HRS cells opening up the possibility to use it as a carrier for a toxin. This antibody also induces antibody-dependent, cell-mediated cytotoxicity in CD30, CD137-double positive HRS cells. The enhances specificity of the CD30, CD137 bispecific antibody to HRS cells makes it a promising candidate for development as a novel HL treatment.
Identifiants
pubmed: 31616638
doi: 10.3389/fonc.2019.00945
pmc: PMC6768943
doi:
Types de publication
Journal Article
Langues
eng
Pagination
945Informations de copyright
Copyright © 2019 Rajendran, Li, Ngoh, Wong, Cheng, Wang and Schwarz.
Références
Am J Pathol. 2012 Sep;181(3):795-803
pubmed: 22901750
Blood. 2001 Jan 1;97(1):250-5
pubmed: 11133768
Eur J Immunol. 1998 Mar;28(3):881-90
pubmed: 9541583
Leuk Lymphoma. 2019 May 6;:1-8
pubmed: 31058559
Nucleic Acids Res. 2002 Jan 15;30(2):E9
pubmed: 11788735
Blood. 2016 Sep 22;128(12):1562-6
pubmed: 27432875
MAbs. 2014 May-Jun;6(3):765-73
pubmed: 24671001
Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11187-92
pubmed: 21690412
Biol Chem. 2018 May 24;399(6):511-523
pubmed: 29533902
J Cell Physiol. 2019 Nov;234(11):21076-21088
pubmed: 31025383
J Biol Chem. 1999 Jun 25;274(26):18218-30
pubmed: 10373423
Oncoimmunology. 2013 Dec 1;2(12):e27184
pubmed: 24501691
Biol Cell. 2018 May;110(5):109-124
pubmed: 29431186
Oncoimmunology. 2016 Apr 29;5(6):e1160188
pubmed: 27471634
Am J Hematol. 2015 Dec;90(12):1128-34
pubmed: 26349012
Nat Biotechnol. 2012 Jul 10;30(7):631-7
pubmed: 22781692
Curr Hematol Malig Rep. 2017 Aug;12(4):358-369
pubmed: 28780614
Cancer Lett. 2016 Sep 28;380(1):243-52
pubmed: 26474544
Blood. 2011 Apr 21;117(16):4208-17
pubmed: 21263152
J Clin Oncol. 2012 Jun 20;30(18):2183-9
pubmed: 22454421
J Clin Invest. 2012 Oct;122(10):3439-47
pubmed: 23023715
Stem Cell Investig. 2017 Apr 19;4:32
pubmed: 28529947
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Blood Cancer J. 2017 Sep 8;7(9):e603
pubmed: 28885612
Cancer Res. 2013 Jan 15;73(2):652-61
pubmed: 23204227